Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
February 26, 2021
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition with cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Videos
Real-World Treatment Patterns, Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer
February 25, 2021
Stephen Freedland, MD, discusses study results exploring real-world evidence on survival outcomes among men who initiated ADT or ADT combined with anti-androgens, docetaxel, or abiraterone.
Videos
Hospital Efficiency Impact on Quality of Prostate Cancer Care
February 25, 2021
Ravi Jayadevappa, PhD, MS, discusses the association between hospital efficiency and quality of care in African American, Hispanic, and white Medicare beneficiaries with prostate cancer.
Videos
Definitive vs Conservative Treatments for Older Men With Prostate Cancer
February 24, 2021
Sagar Patel, MD, discusses utilization trends and survival outcomes among guideline-supported treatment options in older men with high-risk prostate cancer.
Videos
Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
February 23, 2021
Tomasz Beer, MD, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic CRPC.
Videos
Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists
February 21, 2021
Ajeet Gajra, FACP, MD, discusses differences in referral patterns and treatment preferences between medical oncologists and urologists for patients with advanced prostate cancer.
Videos
Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC
February 21, 2021
Felix Feng, MD, discusses results from exploratory analysis of the phase 3 SPARTAN trial, which investigated potential biological signatures of patients with nonmetastatic CRPC who achieved long-term responses to apalutamide and placebo.
Videos
Clinician-Facing Decision Tool to Promote Access to Prostate Cancer Clinical Trials
February 20, 2021
Hala Borno, MD, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
February 19, 2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Videos
Radical Prostatectomy for Low-Risk Prostate Cancer: Incidence and Cost
February 19, 2021
David Gill, MD, discusses the incidence and cost of radical prostatectomy for NCCN low-risk prostate cancer in the state of Utah.
Videos
Reductions in PSA Screening Associated With Increased Incidence of Prostate Cancer in US
February 19, 2021
Vidit Sharma, MD, discusses a study exploring whether reductions in PSA screening are responsible for increased incidence of metastatic prostate cancer in the United States.
Videos
Out-of-Pocket Costs of Oral Hormonal Therapies High for Patients With Prostate Cancer
February 19, 2021
Eric Schwartz, MD, discusses results from an analysis examining out-of-pocket costs for patients with prostate cancer prescribed abiraterone or enzalutamide.
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
February 19, 2021
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Videos
PTEN Loss of Function Associated With Worse Survival in Metastatic CRPC
February 19, 2021
Shilpa Gupta, MD, discusses patient characteristics and survival outcomes by PTEN loss of function status among patients with metastatic CRPC in real-world practice.
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
February 18, 2021
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Videos
Symptom Burden, Functional Status of Hospitalized Patients With Genitourinary Cancers vs Other Cancers
February 18, 2021
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Conference Coverage
Adverse Events in Patients With Prostate Cancer Receiving Apalutamide or Enzalutamide
February 16, 2021
Results from a real-world study highlight the clinical and resource utilization burden of adverse events among patients with prostate cancer treated with apalutamide and enzalutamide.
Conference Coverage
Real-World Cardiotoxicity of Abiraterone vs Enzalutamide for Prostate Cancer
February 16, 2021
Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.
Videos
Apalutamide Plus ADT Improves Long-Term Survival in Metastatic Castration-Sensitive Prostate Cancer
February 15, 2021
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.
Videos
Apalutamide Added to Abiraterone Acetate Plus Prednisone Improves Outcomes in Metastatic CRPC
February 13, 2021
Fred Saad, MD, discusses final results from the phase 3 ACIS trial, which compared apalutamide vs placebo in combination with abiraterone acetate plus prednisone in metastatic CRPC.